Evidence map›Paper›PMID 41623671›Full record

ArticleJournal of clinical practice and research2025

İrem Yayla, Okan Aydoğan, Ayşenur Kılıç, Leyla Sirekbasan, Ayşe İstanbullu Tosun, Bekir Kocazeybek, Harika Öykü Dinç

Abstract read
In one paragraph

Article in Journal of clinical practice and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

İrem YaylaDepartment of Pharmaceutical Microbiology, Bezmialem Vakıf University Faculty of Pharmacy, İstanbul, Türkiye.
Okan AydoğanDepartment of Medical Microbiology, İstanbul Medipol University Faculty of Medicine, İstanbul, Türkiye.
Ayşenur KılıçDepartment of Pharmaceutical Microbiology, Bezmialem Vakıf University Faculty of Pharmacy, İstanbul, Türkiye.
Leyla SirekbasanDepartment of Medical Microbiology, İstanbul Medipol University Faculty of Medicine, İstanbul, Türkiye.
Ayşe İstanbullu TosunDepartment of Medical Microbiology, İstanbul Medipol University Faculty of Medicine, İstanbul, Türkiye.
Bekir KocazeybekDepartment of Medical Microbiology, İstanbul University-Cerrahpaşa Faculty of Medicine, İstanbul, Türkiye.
Harika Öykü DinçDepartment of Medical Microbiology, Üsküdar University Faculty of Medicine, İstanbul, Türkiye.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The increase in antimicrobial resistance poses a significant challenge in medicine, necessitating the exploration of novel antimicrobial agents. Temporin A and Apidaecin B, two naturally occurring antimicrobial peptides (AMPs), have garnered attention for their potent bactericidal properties. This study aimed to investigate the antimicrobial activities of Temporin A and Apidaecin B against clinical strains isolated from blood cultures and evaluate their potential as alternative therapeutic agents. A total of 12

Indexed as

Apidaecin BE. coliS. aureusS. epidermidisTemporin A

Identifiers

PMID41623671
PMCPMC12852080

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.